Determination of HER2 status using both serum HER2 levels and circulating tumor cells in patients with recurrent breast cancer whose primary tumor was HER2 negative or of unknown HER2 status
2007

Determining HER2 Status in Recurrent Breast Cancer Patients

Sample size: 77 publication Evidence: moderate

Author Information

Author(s): Tanja Fehm, Sven Becker, Silke Duerr-Stoerzer, Karl Sotlar, Volkmar Mueller, Diethelm Wallwiener, Nancy Lane, Erich Solomayer, Jonathan Uhr

Primary Institution: University of Tuebingen

Hypothesis

Can serum HER2 levels and circulating tumor cells (CTCs) help determine HER2 status in patients with recurrent breast cancer whose primary tumor was HER2 negative or unknown?

Conclusion

Some patients with initially negative or unknown HER2 status can have elevated serum HER2 levels and/or HER2-positive CTCs at the time of metastatic disease.

Supporting Evidence

  • Twenty out of 77 patients had elevated serum levels of HER2.
  • Concordance between HER2 status of CTCs and serum HER2 was observed in 15 of 21 patients (71%).
  • Twenty-three out of 77 patients were HER2 positive using at least one method.

Takeaway

Some breast cancer patients who were thought to be negative for a certain protein might actually have it when they get worse, and we can find it in their blood.

Methodology

Blood samples were taken from 77 patients, and serum HER2 levels were measured using an ELISA kit while CTCs were detected using immunomagnetic enrichment and characterized by phenotyping and genotyping.

Potential Biases

Potential bias due to the small number of patients and the reliance on non-invasive methods for HER2 status assessment.

Limitations

The study had a small sample size and only a limited number of patients had their HER2 status reassessed using metastatic tissue.

Participant Demographics

{"age":{"under_50":17,"over_50":60},"primary_tumor_size":{"pT1":25,"pT2-4":40,"PTx":12},"nodal_status":{"no":22,"n1":39,"nx":16},"estrogen_receptor_status":{"negative":20,"positive":45,"unknown":12},"progesterone_receptor_status":{"negative":25,"positive":39,"unknown":13},"HER2_status":{"negative":44,"unknown":33},"localization_of_metastases":{"visceral":25,"bone":13,"multiple":39}}

Statistical Information

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1186/bcr1783

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication